Condition: Preeclampsia · Immunologic Disease · Antiphospholipid Antibody Syndrome Primary · Sponsor: IRCCS San Raffaele
The purpose of the study is to evaluate the ability of placental angiogenesis markers to predict the risk of PE in pregnancy in women with primary APS. To construct reference intervals of placental angiogenesis markers specific to women affected by primary APS in pregnancy by measuring the levels of sFlt-1and PlGF in serum maternal serum and their sFlt-1/PlGF ratio during the trimesters of gestation (I TM, II TM and III TM). For this aim the study will involve recruiting two groups of subjects, one will be cases and one will be controls.
This description comes directly from the study's public registry record.
Patrizia Rovere Querini · +390226436095 · rovere.patrizia@hsr.it
Valentina Canti · +390226436095 · canti.valentina@hsr.it
Always discuss trial participation with your own doctor first.
| San Raffaele Hospital | Milan, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05786235